Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03PQW
|
|||
| Former ID |
DNCL002439
|
|||
| Drug Name |
BAY 79-4620
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
Bayer HealthCare Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carbonic anhydrase IX (CA-IX) | Target Info | . | [2] |
| KEGG Pathway | Nitrogen metabolism | |||
| Pathway Interaction Database | HIF-1-alpha transcription factor network | |||
| Reactome | Regulation of gene expression by Hypoxia-inducible Factor | |||
| Reversible hydration of carbon dioxide | ||||
| WikiPathways | Vitamin D Receptor Pathway | |||
| Reversible Hydration of Carbon Dioxide | ||||
| Regulation of Hypoxia-inducible Factor (HIF) by Oxygen | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01028755) To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Therapeutic mechanism and efficacy of the antibody-drug conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Mol Cancer Ther. 2012 Feb;11(2):340-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.